Encouraging Phase 3 Results: Marstacimab for Hemophilia A or B with Inhibitors
Heme Today shared a thrilled post on LinkedIn:
”ICYMI in hemophilia reporting on Heme Today: Marstacimab from Pfizer performed impressively in a phase 3 study as tx for hemophilia A or B with inhibitors.”
To learn more, follow the link.
A phase 3 study has yielded favorable topline results for Marstacimab (HYMPAVZI), showing promising efficacy and safety in treating severe hemophilia A or B with inhibitors.
Pfizer announced the positive findings, highlighting the therapy’s potential to address an important unmet need for patients with antibodies that limit factor-based prophylaxis.
“These encouraging results demonstrate HYMPAVZI’s potential to help people living with hemophilia A or B with inhibitors, meeting an important need for patients with antibodies that neutralize most factor-based prophylactic options used to manage bleeding episodes,” commented Pfizer’s chief inflammation & immunology officer Michael Vincent, MD, PhD.
Stay updated on the latest scientific advancements in the field of hemophilia management with Hemostasis Today.
-
Jun 3, 2026, 05:35David McIntosh: Do Current Global Blood and Plasma Systems Provide the Care Patients Deserve?
-
Jun 3, 2026, 05:16WFH Highlights the Vision for Health Equity in Bleeding Disorders at WHA79
-
Jun 3, 2026, 04:12Lynne Baird: Why Bleed Control Kits Belong in Every Public Space
-
Jun 2, 2026, 19:42Sékouba Sidimé: vWD vs Hemophilia A – The Classic USMLE Step 1 trap in Hematology
-
Jun 2, 2026, 19:41Bassem M. Mohammed: How Factor VIII Interacts To Procoagulant Membranes To Support Activation Of Blood Clotting
-
Jun 2, 2026, 19:28Looking Beyond Bleeding Control To Understand Inflammation In Hemophilic Arthropathy – CRH French Reference Center for Hemophilia Lyon
-
Jun 2, 2026, 19:27Francisco Chacón-Lozsán: Coma Is Not a Diagnosis – Final Pathway Of Brain Arousal And Awareness Failure
-
Jun 2, 2026, 19:26Panagiotis Papanagiotou: Recognizing CVST On T2 MRI
-
Jun 2, 2026, 17:56Coralie Delporte Gravouil: Scientific Program 2026 – Essentials of Hemostasis Now Available